Producing better drugs
4 Feb 2016 - 1 min
The question driving the drug design cycle will need to change from “which is the next compound in the series to synthesize?” to “how do we evaluate the more complex and conflicting data...
Our colleague Scott Lusher was interviewed by Elsevier on facilitating data-driven decisions in drug development: Technology can support the use of “big data” for drug design and optimization, but not without a shift in mentality. “It is becoming increasingly obvious that the rapidly growing amounts of data that should inform drug discovery do not fit current design workflows. This situation will need to change.”